Targeted therapies in brain metastases

Area of Science:

• Oncology
• Neurology
• Pharmacology

Background:

• Brain metastases represent a significant clinical challenge in advanced cancers, including breast, lung, melanoma, and renal cell carcinoma.
• Current treatment paradigms for brain metastases primarily involve radiotherapy (whole brain radiotherapy or stereotactic radiosurgery) or surgery for select cases.
• Limited established standards of care exist for patients progressing after initial treatments for brain metastases.

Purpose of the Study:

• To review the evolving role of systemic therapies, particularly targeted agents, in managing brain metastases from solid tumors.
• To highlight the observed central nervous system (CNS) activity of specific targeted therapies in various cancer types.
• To discuss future directions for optimizing targeted therapy efficacy within the CNS.

Main Methods:

• Review of existing literature on systemic and targeted therapies for brain metastases.
• Analysis of clinical trial data and case reports detailing CNS activity of targeted agents.
• Exploration of treatment strategies for refractory or progressive brain metastases.

Main Results:

• Lapatinib demonstrates activity in HER2-positive breast cancer brain metastases, both initially and upon progression.
• Gefitinib and erlotinib show CNS activity in non-small cell lung cancer (NSCLC) brain metastases.
• BRAF inhibitors (vemurafenib, dabrafenib) and ipilimumab exhibit CNS activity in melanoma brain metastases.

Conclusions:

• Targeted therapies are increasingly important in treating brain metastases, offering new options beyond traditional radiotherapy and surgery.
• Further research is needed to optimize the use and incorporation of targeted agents into treatment protocols for brain metastases.
• Improving outcomes for patients with brain metastases requires a better understanding of how to maximize the CNS efficacy of systemic therapies.